Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias

Genes Chromosomes and Cancer

Volumn 47, Issue 1, 2008, Pages 56-63

  Belge, Gazanfer ^a   Meyer, Anke ^a   Klemke, Markus ^a   Burchardt, Käte ^b   Stern, Corinna ^c   Wosniok, Werner ^a   Loeschke, Siegfried ^a   Bullerdiek, Jörn ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b General Hospital Bremen Mitte   (Germany)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; HIGH MOBILITY GROUP A2 PROTEIN; MOLECULAR MARKER; PARAFFIN;

ADULT; AGED; ANALYTIC METHOD; ANAPLASTIC CARCINOMA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYONAL TISSUE; FEMALE; FOLLICULAR CARCINOMA; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; UPREGULATION;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC MARKERS; HMGA2 PROTEIN; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 36549087198     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20505     Document Type: Article

References (40)

1. Antonov J, Goldstein DR, Oberli A, Baltzer A, Pirotta M, Fleischmann A, Altermatt HJ, Jaggi R. 2005. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85:1040-1050.
2. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K. 1995. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82:57-65.
3. Baloch ZW, LiVolsi VA. 2002. Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 117:143-150.
4. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. 2002. Diagnosis of "follicular neoplasm": A gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 26:41-44.
5. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. 2002. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21:2971-2980.
6. Blank C, Rogalla P, Tran KH, Bullerdick J. 2000. A novel high mobility group protein gene is a candidate for Xp22 abnormalities in uterine leiomyomas and other benign tumors. Cancer Genet Cytogenet 121:172-180.
7. Burma KD. 2006. Micropapillary thyroid cancer. Should we aspirate all nodules regardless of size? J Clin Endocrinol Metab 91:2043-2046.
8. Bustin M, Reeves R. 1996. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54:35-100.
9. Castro MR, Gharib H. 2005. Continuing controversies in the management of thyroid nodules. Ann Intern Med 142:926-931.
10. Chau KY, Patel UA, Lee KL, Lam HY, Crane-Robinson C. 1995. The gene for the human architectural transcription factor HMGI-C consists of five exons each coding for a distinct functional element. Nucleic Acid Res 23:4262-4266.
11. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V, Fusco A. 1995. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10:1307-1314.
12. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A. 1996. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13:2439-2446.
13. Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A. 1998. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58:4193-4198.
14. Czyz W, Balcerczak K, Jakubiak M, Pasicka Z, Kuzdak K, Mirowski M. 2004. HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma. Langenbecks Arch Surg 389:193-197.
15. Feilchenfeldt J, Totsch M, Sheu SY, Robert J, Spiliopoulos A, Frilling A, Schmid KW, Meier CA. 2003. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol 16:1117-1123.
16. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. 2005. Management of thyroid nodules detected at US: Society of radiologists in ultrasound consensus conference statement. Radiology 237:794-800.
17. Fryknäs M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A. 2006. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumor Biol 27:211-220.
18. Goellner JR, Gharib H, Grant CS, Johnson DA. 1987. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 31:587-590.
19. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, Groshen S, Singer P, Lopresti J, Martin SE. 2000. Follicular lesions of thyroid: A 5-year fine-needle aspiration experience. Cancer 90:335-341.
20. Harrer M, Luhrs H, Bustin M, Scheer U, Hock R. 2004. Dynamic-interaction of HMGA1a proteins with chromatin. J Cell Sci 117:3459-3471.
21. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. 1998. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23:350-357.
22. Kebebew E, Peng M, Reiff K, Duh QY, Clark OH, McMillan A. 2006. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J Surg 30:767-774.
23. LiVolsi VA. 2003. Can we agree to disagree? Hum Pathol 34:1081-1082.
24. LiVolsi VA, Asa SL. 1994. The demise of follicular carcinoma of the thyroid gland. Thyroid 4:233-236.
25. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. 2004. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64:2024-2029.
26. Niedziela M, Maceluch J, Korman E. 2002. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab 87:4411-4415.
27. Reeves R, Nissen MS. 1990. The A.T-DNA-binding domain of mammalian high mobility group 1 chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265:8573-8582.
28. Reeves R, Beckerbauer L. 2005. HMGI/Y proteins: Flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519:13-29.
29. Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, Dinis J, Catarino A, Pereira T, Leite V. 2007. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep 18:917-926.
30. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. 1996. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149:775-779.
31. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. 1997. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: Relationship to histologic grade. Mol Carcinog 19:153-156.
32. Rogalla P, Blank C, Helbig R, Wosniok W, Bullerdiek J. 2001. Significant correlation between the breakpoint of rare clonal aberrations in benign solid tumors and the assignment of HMGIY retropseudogenes. Cancer Genet Cytogenet 130:51-56.
33. Roti E, Rossi R, Trasforini G, Bertelli F, Ambrosio MR, Busutti L, Pearce EN, Braverman LE, Degli Uberti EC. 2006. Clinical and histological characteristics of papillary thyroid microcarcinoma: Results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91:2171-2178.
34. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S, Anttila S. 2006. Increased expression of high mobility group A proteins in lung cancer. J Pathol 209:206-212.
35. Schoenmakers EF, Wanschura S, Mols R, Bullerdick J, Van den Berghe H, Van de Ven WJ. 1995. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10:436-444.
36. Sheils O. 2005. Molecular classification and biomarker discovery in papillary thyroid carcinoma. Expert Rev Mol Diagn 5:927-946.
37. Smith J, Cheifetz RE, Schneidereit N, Berean K, Thomson T. 2005. Can cytology accurately predict benign follicular nodules? Am J Surg 189:592-595.
38. Strichman-Almashanu LZ, Bustin M, Landsman D. 2003. Retroposed Copies of the HMG Genes: A window to genome dynamics. Genome Res 13:800-812.
39. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CF, Ringel MD, Eng C. 2005. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90:2512-2521.
40. Wolffe AP. 1994. Architectural transcription factors. Science 264:1100-1101.